Bruker Corporation (NASDAQ:BRKR) Relative Strength Index (RSI) is 64.64, with weekly volatility at 7.47% and ATR at 2.52. The BRKR stock’s 52-week price range has touched low of $30.78 and a $69.92 high. Intraday shares traded counted 0.35 million, which was 29.47% higher than its 30-day average trading volume of 498.02K. Its shares traded higher over the last trading session, gaining 0.85% on 02/19/21. The shares fell to a low of $61.93 before closing at $62.88. BRKR’s previous close was $62.35 while the outstanding shares total 153.20M. The firm has a beta of 1.29, a 12-month trailing P/E ratio of 61.47, and a growth ratio of 6.73.
Investors have identified the Medical Devices company Bruker Corporation as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $9.55 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Bruker Corporation (BRKR) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For BRKR, the company has in raw cash 567.1 million on their books with 1.7 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on a decline. In terms of their assets, the company currently has 1.83 billion total, with 683.2 million as their total liabilities.
Having a look at the company’s valuation, the company is expected to record 2.02 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on BRKR sounds very interesting.
Is the stock of BRKR attractive?
In related news, Director, Kastner Marc A sold 1,236 shares of the company’s stock in a transaction that recorded on Jan 07. The sale was performed at an average price of 56.56, for a total value of 69,908. As the sale deal closes, the Director, Friend Cynthia M now sold 1,800 shares of the company’s stock, valued at 97,776. Also, Director, Friend Cynthia M sold 3,473 shares of the company’s stock in a deal that was recorded on Dec 15. The shares were price at an average price of 54.95 per share, with a total market value of 190,841. Following this completion of acquisition, the Pres. & CEO, Bruker EST, Prause Burkhard now holds 5,000 shares of the company’s stock, valued at 239,650. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.20%.
4 out of 13 analysts covering the stock have rated it a Buy, while 8 have maintained a Hold recommendation on Bruker Corporation. 1 analysts has assigned a Sell rating on the BRKR stock. The 12-month mean consensus price target for the company’s shares has been set at $64.67.